1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Expert Analysis: EU Commission's Proposed Regulation On Health Technology Assessment

An HTA proposal from the European Commission represents a new step toward harmonized market access for health technologies in the EU. Simmons & Simmons lawyers Annabelle Bruyndonckx and Vladimir Murovec provide an expert view on the proposal, its impact on the medtech sector and how it relates to the EU Medical Device and IVD Regulations.

Concept of national healthcare system - EU - European Union
About The Authors

Annabelle Bruyndonckx is a counsel with Simmons & Simmons LLP, focusing on all parts of medicinal product and medical device lifecycles, from R&D and qualification, to marketing authorization/CE-marking, to pricing & reimbursement, manufacture and distribution, compliance, and more.

Vladimir Murovec is an associate with Simmons & Simmons LLP, advising on a wide range of regulatory issues relating to medicines, medical technologies and digital health solutions, including product qualification, (early) market access procedures, marketing, distribution, advertising, and monitoring of products.

On Jan. 31, the EU Commission published a proposal for a regulation (the "Draft Regulation") on health technology assessments (HTA; SWD[2018] 42 final) and amending a 2011 Cross-Border Healthcare Directive (CBD; 2011/24/EU). Also see "Revolutionary EU HTA Cooperation Proposal Will Use MDR/IVDR Platforms" - Medtech Insight, 1 February, 2018.

This draft HTA regulation builds on the collaboration and methodology pursued for more than 10 years by the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 
• By Amanda Maxwell

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.

Final Curtain For LDTs? FDA Will Not Appeal District Court Decision To Vacate Final Rule

 
• By Brian Bossetta

The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

More from Policy & Regulation

Global Medtech Guidance Tracker: May 2025

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.

More Haste Less Pace? Challenging The ‘Early As Possible’ Principle In Medtech Innovation

 
• By Stuart Grant

The rallying cry to start as early as possible has become increasingly common in the world of medical device development. Innovation expert Dr. Stuart Grant challenges this conventional wisdom, asking: Is "sooner" truly better, or is there a smarter path to market for your medical device?

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 
• By Natasha Barrow

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.